ADVA
26.4.2022 09:02:06 CEST | Business Wire | Press release
ADVA (FSE: ADV) today announced that Schleswig-Holstein Netz, one of northern Germany’s largest power grid operators, has successfully completed a field trial of quantum-secured data transport using the ADVA FSP 3000 platform with ConnectGuard™ Layer 1 encryption technology. For the first time with a full commercial solution, a future-proof key exchange based on quantum key distribution (QKD) was used to encrypt data across overhead fiber cables. Until now, ensuring QKD performance in the harsh outdoor conditions of aerial fiber was thought to be a major barrier. The trial shows how mission-critical utility networks can now counter the urgent threat of attacks from quantum computers. Technology from ADVA’s partner, the quantum cryptography company ID Quantique, also played a significant role generating QKD keys.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220425005727/en/
“The emergence of large quantum computers will jeopardize mission-critical networks like never before. That’s why we’re taking action now and trialing technology to safeguard power infrastructure for the long term. The success of our PoC with ADVA’s secure solution is a key breakthrough for protecting utility networks with QKD,” said Benjamin Merkt, CTO of Schleswig-Holstein Netz. “We’ve shown that grids like ours that use aerial fiber stretching across hundreds of kilometers can be protected against quantum-enabled hacking, even in adverse climactic conditions. It’s a major step towards guaranteeing the integrity and security of critical data in transit both today and in the post-quantum world.”
QKD offers a way to secure sensitive data transport against all forms of cyberattack, including from quantum computers that could render traditional public key cryptography useless. Distributing encryption keys in a quantum state ensures that any attempt to intercept traffic disturbs photons, introducing coding errors and alerting operators. But implementing the technology in power infrastructure is challenging as most utility communication networks are integrated with long-distance high-voltage overhead lines. As QKD performance can be easily affected by environmental factors, stability was a key criterion in Schleswig-Holstein Netz’s trial, but the configuration proved to be stable and suitable for aerial fiber. The success of ADVA’s solution shows a way forward for quantum-secure utility networks.
“This PoC proves that QKD-based encryption is achievable in network architectures like this. Even with fiber optics integrated with 110kV overhead lines and unprotected from wind, solar radiation and thunderstorms, our solution was successful,” commented Helmut Griesser, director of advanced technology at ADVA. “Working closely with Schleswig-Holstein Netz and our partner ID Quantique, we’ve been able to demonstrate that QKD has a major role in safeguarding utilities. We’ve shown that our FSP 3000 ConnectGuard™ encryption has the power to protect our most sensitive and vital assets from cybercriminals even in the age of quantum computers.”
The PoC was performed as part of the OPENQKD project , which is supported by the European Union’s Horizon 2020 research and innovation program. The project creates several testbeds and demonstrates numerous use cases, laying the foundations of a pan-European quantum network.
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
About ID Quantique
Founded in 2001 as a spin-off of the Group of Applied Physics of the University of Geneva, ID Quantique is the world leader in quantum-safe crypto solutions, designed to protect data for the future. The company provides quantum-safe network encryption, secure quantum key generation and Quantum Key Distribution solutions and services to the financial industry, enterprises and government organizations globally. IDQ’s quantum random number generator has been validated according to global standards and independent agencies, and is the reference in highly regulated and mission critical industries – such as security, encryption, critical infrastructure and IoT – where trust is paramount. For more information, please visit www.idquantique.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220425005727/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release
Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
